We report the occurrence of the syndrome of inappropriate antidiuretic hormone secretion in 3 patients with breast carcinoma metastatic to the liver who received hepatic arterial infusion of vinblastine at lower doses than those previously associated with this effect. Leukopenia was severe in all patients, who additionally experienced hypokalemia with excessive kaliuresis. The etiology of the observed hypokalemia is unclear. We suspect that vinblastine may induce renal tubular dysfunction. These toxicities appear dose-related.
Get full access to this article
View all access options for this article.
References
1.
AntonyA., RobinsonW.A., RoyC., PelanderW., DonohueR.: Inappropriate antidiuretic hormone secretion after high dose vinblastine.J. Urol., 123: 783–784, 1980.
2.
BartterF.C., SchwartzW.B.: The syndrome of inappropriate secretion of antidiuretic hormone.Am. J. Med., 42: 790–806, 1967.
3.
CuttingH.O.: Inappropriate secretion of antidiuretic hormone secondary to vincristine therapy.Am. J. Med., 51: 269–271, 1971.
4.
FraschiniG., YapH.Y., HortobagyiG.N., BuzdarA.U., BlumenscheinG.R.: Five-day continuous infusion vinblastine in the treatment of breast cancer.Cancer, 56: 225–229, 1985.
5.
FraschiniG., FleishmanG., YapH.Y., CarrascoH.C., CharnsangavejC., PattY., HortobagyiG.N.: Percutaneous hepatic arterial infusion of cisplatin for metastatic breast cancer.Cancer Treat. Rep., 71: 313–315, 1987.
6.
FraschiniG., FleishmanG., CharnsangavejC., CarrascoH.C., HortobagyiG.N.: Continuous 5-day infusion of vinblastine for percutaneous hepatic arterial chemotherapy of metastatic breast cancer.Cancer Treat. Rep. (in press).
7.
FraschiniG., CharnsangavejC., CarrascoH.C., JabbouryK., HortobagyiG.N.: Percutaneous hepatic arterial infusion of cisplatin-vinblastine for refractory breast carcinoma metastatic to the liver.Am. J. Clin. Oncol. (in press).
8.
GinsbergS.J., ComisR.L., FitzpatrickA.V.: Vinblastine and inappropriate ADH secretion.N. Engl. J. Med., 296: 941, 1977.
9.
LevinL., SealyR., BarronJ.: Syndrome of inappropriate antidiuretic hormone secretion following cis-dichlorodiammineplatinum II in a patient with malignant thymoma.Cancer, 50: 2279–2282, 1982.
10.
LittlewoodT.J., Peter SmithA.: Syndrome of inappropriate antidiuretic hormone secretion due to treatment of lung cancer with cisplatin.Thorax, 39: 636–637, 1984.
OwellenR.J., HartkeC.A.: The pharmacokinetics of 4-acetyltritium vinblastine in two patients.Cancer Res., 35: 975–980, 1975.
13.
PorterA.T.: Syndrome of inappropriate antidiuretic hormone secretion during cis-dichlorodiammineplatinum therapy in a patient with an ovarian carcinoma.Gynecol. Oncol., 21: 103–105, 1985.
14.
RavikumarT.S., GrageT.B.: The syndrome of inappropriate ADH secretion secondary to vinblastine-bleomycin therapy.J. Surg. Oncol., 24: 242–245, 1983.
15.
RobertsonG.L., BhoopalamN., ZelkowitzL.J.: Vincristine neurotoxicity and abnormal secretion of antidiuretic hormone.Arch. Intern. Med., 132: 717–720, 1973.
16.
RollasonT.P., BrewerD.B., BlissD.J.: An electron microscopic study of the effects of vinblastine sulphate on the ultrastructure of the kidney, trachea, liver, peripheral nerve and small intestine of the rat.J. Pathol., 140: 91–112, 1983.
17.
StahelR.A., OelzO.: Syndrome of inappropriate ADH secretion secondary to vinblastine.Cancer Chemother. Pharmacol., 8: 253–254, 1982.
